Etrasimod

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 155 publications

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Pharmacological properties and clinical efficacy of sphingosine 1-phosphate (S1P) receptor modulator, Etrasimod (Velsipity® 2 mg tablets)

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: September 02, 2026

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

PANCCO Clinical Practice Guideline Update for the treatment of ulcerative colitis in adults

Journal: Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru

Published: July 25, 2026

S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.

S1P receptor modulators for moderate-to-severe ulcerative colitis: a systematic review, meta-analysis, and trial sequential analysis.

Journal: Journal of gastroenterology

Published: July 06, 2026

Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy.

Beyond the Colon: Acute Hemolysis Associated With Etrasimod Therapy.

Journal: Cureus

Published: June 23, 2026

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.

Journal: Paediatric drugs

Published: May 26, 2026

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis

Published: May 20, 2026

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Journal: Internal medicine (Tokyo, Japan)

Published: May 17, 2026

Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms.

Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms.

Journal: Frontiers in gastroenterology (Lausanne, Switzerland)

Published: April 20, 2026

Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.

Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.

Journal: British journal of clinical pharmacology

Published: April 15, 2026

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators.

Journal: Drugs & aging

Published: April 07, 2026

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: The Annals of pharmacotherapy

Published: March 27, 2026

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program.

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program.

Journal: Therapeutic advances in gastroenterology

Published: March 24, 2026

Showing 1-12 of 155

Last Updated: 09/26/2026